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1. Background
1.1. Introduction
Globally there are 430,000 new diagnoses of bladder cancer and
over 165,000 deaths every year [1]. It is a deadly disease with only
50% of those diagnosed surviving at 10 years [2].
The most common presentation for bladder cancer is haema-
turia. Patients with suspected bladder cancer are referred to sec-
ondary care where a urologist takes focussed history and
examination, carries out a cystoscopy [3] and requests imaging,
urine and blood tests (Fig. 1). Cystoscopy is the gold standard test
used to diagnose bladder cancer. The imaging test is used to assess
the upper tracts for malignant (renal or upper tract urothelial can-
cer) or benign causes of haematuria (e.g. urinary stones) [4].
The bladder cancer rate in patients referred with visible haema-
turia is 18.9% but only 4.8% in those referred with non-visible
haematuria [5]. Upper tract urothelial cancer (UTUC) is rare with
an estimated annual incidence of 2 cases per 100,000 inhabitants
[2]. Less than 1% of patients referred to secondary care with haema-
turia have UTUC [6]. A large proportion of patients investigated
therefore will have unnecessary, invasive procedures. Cystoscopy
causes discomfort and can carry risks such as infection and bleeding
and the radiation from a CT scan is associated with secondary malig-
nancy [7]. Equivocal tests can lead to further invasive testing, e.g.
biopsy under general anaesthetic, to confirm a negative finding.
Annual costs of these investigations are significant. In the UK,
patients with normal results from haematuria investigations cost
the National Health Service £33.5 million annually [8].
International guidelines for suspected cancer referral pathways
vary greatly. Established risk factors are not featured in referral cri-
teria. This may be due to a lack of high-quality evidence. The AUA
(American Urological Association) and UK NICE (National Institute
for Clinical Excellence) guidelines differentiate between visible and
non-visible haematuria, but the evidence behind this is low [9,10].
Both give different age thresholds for recommended investigation
of each type of haematuria. These arbitrary thresholds are derived
from observation of cancer detection rates for wide age-group cat-
egories. In the UK, a National Institute for Health Research (NIHR)
Health Technology Assessment systematic review highlighted the
uncertainty in the optimal diagnostic pathway for haematuria
and specified that future studies should address this [11].
1.2. Rationale
There is currently no published data describing the variation of
current diagnostic strategies and respective cancer yield. Some alter-
native strategies have been proposed, e.g. the use of CT urography as
a triage test to avoid performing 17% of flexible cystoscopies [12].
However, a predictive modelling study suggested CT urography in
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patients with a low risk of urinary tract malignancy may cause more
cancers than it diagnoses due to a high radiation dose [13].
Considering the rarity of upper tract cancers, there is a need for
a large-scale study in current clinical practice to investigate the
optimal strategy for urological cancer diagnosis in patients with
haematuria.
IDENTIFY aims to be the largest contemporary study of haema-
turia investigation. It will provide data on the utility of diagnostic
pathways for bladder and upper urinary tract cancer in patients
presenting with haematuria, a contemporary evaluation of these
pathways and an assessment of the prevalence of urinary tract can-
cer (bladder cancer, upper tract urothelial cancer, renal cancer and
prostate cancer).
We will assess the predictive ability of recognised risk factors
for urinary tract cancer and explore novel risk factors that could
improve the selection of patients for referral of suspected cancer.
By evaluating the patient factors that predict urinary tract cancer
and subsequently classifying them in to high, medium and low
risk, we will allow clinicians to select the appropriate intensity of
investigations. This risk stratification strategy will prompt earlier
diagnosis and treatment of more aggressive disease by allocating
resources to patients that need them most. It will also optimise
use of the most suitable tests to the patient’s risk of urothelial can-
cer. The ultimate hope is that risk stratification will reduce the
number of invasive procedures and imaging tests performed,
reduce the proportion of negative investigations, and increase can-
cer diagnostic yield.
Since we do not know the best diagnostic strategies to use and
which risk factors are relevant, it was not possible to design an
interventional study comparing different strategies. Therefore we
designed a prospective observational study with a specifically
designed data collection tool.
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Fig. 1. Typical pathway for a patient referred with suspected urinary tract cancer.
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1.3. IDENTIFY pilot study
The IDENTIFY pilot study collected data on the incidence of uro-
logical tract cancer in 824 patients referred with haematuria in
2016, from 7 hospitals in the South of England. It confirmed the
feasibility of the project, the processes required to collect data,
design of data collection instruments and design of the project
management tools for the IDENTIFY study (Appendix A).
2. Methods and analysis
2.1. Study design
The IDENTIFY study is a prospective international multi-centre
observational cohort study carried out in urological secondary care
centres.
2.2. Aims and objectives
The IDENTIFY study aims to develop risk-based diagnostic
strategies for patients referred to secondary care with suspected
urinary tract cancer.
Primary Objective: To determine the prevalence of urinary tract
cancer in patients referred to secondary care with suspected uri-
nary tract cancer.
The secondary objectives are to determine:
 the prevalence of urinary tract cancers in key clinical subgroups
Visible haematuria (VH), Non-visible haematuria (NVH), no
haematuria (NH).
 the prevalence of urinary tract cancers by age group and sex.
 current practices in urinary tract cancer diagnosis across differ-
ent healthcare settings and the effect on prevalence.
 differences in the prevalence of urinary tract cancers in sec-
ondary care in different countries.
 risk factors that predict urinary tract cancers and define clini-
cally useful risk stratification groups.
 the diagnostic accuracy of US, CT and urine cytology for bladder,
renal and UTUC.
 the diagnostic accuracy of flexible cystoscopy for bladder
cancer.
 the cost-effectiveness of different diagnostic strategies for sus-
pected urinary tract cancer
2.3. Study setting
Patient data will be collected from secondary care centres that
evaluate patients with suspected urinary tract cancer and have
the ability to perform cystoscopy. A list of anticipated participating
countries from pre-registered interest in the study can be found in
Table 1.
2.4. Eligibility
Patients are included if they are over 16 years of age and were
referred to secondary care with haematuria (visible or non-visible),
or without haematuria but with suspicious symptoms suggestive
of urinary tract cancer.
Exclusion criteria: Patients with a previous or known diagnosis
of primary urological cancer, patients referred for suspected recur-
rence of primary urological cancer, or patients undergoing cys-
toscopy for a reason unrelated to ruling out urothelial cancer.
Patient records lacking sufficient data to determine the primary
outcome will be excluded.
2.5. Sample size
The sample size was determined pragmatically based on antic-
ipated accrual. Based on a minimum of 50 patient records collected
per site and 100 sites, we plan for a minimum sample size of 5000
patients. Based on the prevalence of urinary tract cancer from the
IDENTIFY pilot study of 12%, a confidence level of 95% and a sample
size of 5000, the precision for the estimate of urinary tract cancer
prevalence will be +/ 0.01%.
2.6. Data collection
Participating collaborators will complete a registration survey
describing their normal protocol for the investigation of haema-
turia at their institution. Data will be collected on consecutive
patients seen for assessment, with a minimum of 50 patients per
centre. Data collected is routine information recorded as part of
clinical assessment. Some patients may undergo further investiga-
tions following their initial tests. These can include biopsies, defini-
tive cancer surgery or transurethral resection of bladder tumour
(TURBT). This data will also be collected, and patients will be fol-
lowed up until histopathology is available (if applicable) or until
the outcome of their haematuria investigations is complete, which-
ever is later. It is not anticipated that follow up for any patient will
exceed 3 months. Where no cancer is found, patients discharged
from secondary care by a urologist will be determined to have
met the clinical threshold for a negative cancer outcome.
Non-identifiable patient data will be collected by individual
investigators using REDCap electronic data capture tool [14,15].
Data will be collected on:
Hospital protocol (if any) for the investigation of patients with
haematuria
Reason for referral
Baseline demographic information
Details of clinical history
Examination findings
Bedside urinalysis
Urine microscopy and cytology results
Blood test results
Ultrasound, CT and other imaging results
Flexible and Rigid cystoscopy results
Histopathology from any biopsies or surgery
Further pathology results within the time frame of the study.
2.7. Quality control
All submitted data will be quality checked by a dedicated inde-
pendent quality control team. Data will be checked for completion,
outliers and adequacy. Queries will be posed to investigators who
will have an opportunity to address any deficiencies.
Missing data: All records will be included in the analysis if there
is sufficient data to determine the primary outcome. The primary
outcome will not be imputed in any case. Missing data will not
Table 1
Anticipated participating countries in the IDENTIFY study.
United Kingdom France Netherlands
Argentina Greece Poland
Australia Hong Kong Portugal
Belgium Hungary Singapore
Canada Iraq Slovenia
China Ireland Spain
Croatia Italy Turkey
Czech Republic Japan Uruguay
Denmark Malaysia USA
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be imputed for univariable analysis. Missing data may be imputed
in multivariable analysis.
Missing results (tests ordered but not completed) and uninter-
pretable results (tests performed but inadequate for assessment)
will be reported, and reasons examined, but omitted from the main
diagnostic test analysis.
2.8. Data analysis plan
We will create a formal statistical analysis plan prior to data
analysis.
Prevalence will be calculated as follows:
Total number of patients with target condition
Total number of patients at risk
The defined population at risk are all patients in the study who
met the eligibility criteria.
We will also calculate prevalence separately for the following
groups:
 Visible haematuria
 Non-visible haematuria
 No haematuria
2.9. Risk factor analysis
We will use multivariate analysis to assess the association of
well-established patient risk factors with individual urinary tract
cancers. We will also assess less established and controversial risk
factors. Together these will be used to develop risk categories for
urinary tract cancers.
2.10. Diagnostic test evaluation
Collaborators will score test results on a three-point scale: Nor-
mal, Equivocal (defined as a valid test with inconclusive findings)
and Positive. Test adequacy will also be recorded [16]. This
includes any intended tests that were not performed, tests that
were attempted but deemed inadequate, and tests that were com-
pleted and were adequate. This will allow for a more accurate diag-
nostic test evaluation. Sensitivity, specificity, negative and positive
predictive values will be reported based on adequately completed
tests. Index tests will be compared against specified reference stan-
dards for the diagnosis of the relevant cancer type.
2.11. Cost effectiveness
Following analysis of results, diagnostic test strategies will be
proposed. The estimated costs of these will be estimated by multi-
plying standard unit costs by key resource use. Where possible,
standard unit costs will be derived from sources such as NHS Ref-
erence costs in the UK. A cost analysis will be performed on the
various diagnostic strategies proposed. The effect of test inade-
quacy or equivocal test results will also be taken into account for
the cost analysis.
3. Ethics and dissemination
Ethical approval and local regulatory approval will be sought as
per local and national guidelines, before commencement of the
study. In the UK this study was deemed exempt from ethical
approval as per Health Research Authority UK guidance and as
per advice from the UK National Research Ethics Service. Each par-
ticipating UK site will obtain local audit department/Research &
Development approval to carry out the study.
Results from the study will be presented in international scien-
tific urological conferences, published in peer-reviewed journals,
and submitted to patient advocate groups. It is our intention that
all collaborators contributing substantially to the work will have
Pubmed indexed collaborator authorship on papers from the study.
4. Guarantor
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Appendix A
IDENTIFY Pilot study – The Investigation and DEtection of urolog-
ical Neoplasia in paTIents reFerred with haematuria: A multicentre
prospective analYsis.
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Khadhouri S, Miller C, Chippagiri A, Moore M, Lobo N, Parsons S,
Campain NJ, McGrath JS.
Introduction and objective
This analysis aims to provide an up-to-date overview of haema-
turia investigations and subsequent urological cancer detection
rate. This is in light of recently updated NICE (National Institute
for Clinical Excellence) referral guidelines for suspected bladder
cancer in June 2015 that aimed to standardise referrals and facili-
tate early detection of urological cancer.
Methods
Prospective data for 824 patients were collected from 7 hospi-
tals in the south of England for all suspected cancer referrals pre-
senting with haematuria. Those with previous urological
malignancy were excluded. Individual hospital protocols for such
referrals were also noted.
Results
491 men and 333 women with a median age of 67 were
included in the study. 301 (36.5%) patients had non-visible haema-
turia (NVH); 523 (63.5%) had visible haematuria (VH). All hospitals
had cystoscopy and ultrasound (USS) as first line investigations
(one hospital used abdominal X-ray alongside USS), and a mixture
of CT, intravenous urogram (IVU) and ureterorenoscopy (URS) as
second line.
The overall prevalence of urological malignancy was 12.2%
(10.4% bladder, 0.6% ureteric/ renal TCC, 1.2% renal); which was
16.4% of the VH group and 5.0% of the NVH group. 85% of malig-
nancies presented with VH. Differences in prevalence existed in
sex and age groups. Bladder cancer was found in 5 patients
younger than 45 years, 4 of whom presented with VH (an age cri-
teria of 45 or older is recommended in the referral guidelines). A
higher percentage of patients with malignancy had a smoking his-
tory vs. non-smokers. Stones accounted for 6.7% of presentations.
95.5% of all malignancies and 94.9% of all pathology were diag-
nosed following an abnormal flexible cystoscopy and/or USS alone.
One renal malignancy and 4 upper tract TCCs that were diagnosed
with second line investigations had a normal USS.
Conclusions
The prevalence of urological malignancy shown in this analysis
compares to previous studies. Second line investigations for upper
tract imaging are variable amongst different hospitals. The major-
ity of malignancies were diagnosed following abnormal first line
investigations with USS for upper tract imaging. Patients with
malignancy were more likely to have a smoking history and pre-
sent with VH.
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